vs
Side-by-side financial comparison of Akso Health Group (AHG) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $7.0M, roughly 1.8× Akso Health Group). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -18.6%, a 269.3% gap on every dollar of revenue.
Akso Health Group is a global healthcare enterprise specializing in the R&D, production, and distribution of generic pharmaceuticals, over-the-counter wellness products, and medical devices. It primarily serves markets in China, Southeast Asia, and North America, with core business segments covering drug manufacturing, medical supply chains, and community healthcare services.
AHG vs SPRO — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.0M | $12.6M |
| Net Profit | $-1.3M | $31.5M |
| Gross Margin | 8.9% | — |
| Operating Margin | -20.5% | — |
| Net Margin | -18.6% | 250.7% |
| Revenue YoY | — | 24080.8% |
| Net Profit YoY | — | 250.9% |
| EPS (diluted) | — | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.6M | ||
| Q3 25 | $7.0M | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $12.0K | ||
| Q4 24 | — | $52.0K | ||
| Q3 24 | — | $65.0K | ||
| Q2 24 | — | $114.0K | ||
| Q1 24 | — | $140.0K |
| Q4 25 | — | $31.5M | ||
| Q3 25 | $-1.3M | $-7.4M | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | $-13.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-17.1M | ||
| Q2 24 | — | $-17.9M | ||
| Q1 24 | — | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | 8.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -20.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -122758.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -28604.6% | ||
| Q2 24 | — | -16720.2% | ||
| Q1 24 | — | -9987.1% |
| Q4 25 | — | 250.7% | ||
| Q3 25 | -18.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -115550.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -26380.0% | ||
| Q2 24 | — | -15668.4% | ||
| Q1 24 | — | -9049.3% |
| Q4 25 | — | $0.56 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.25 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.32 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.1M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $198.3M | $59.0M |
| Total Assets | $212.0M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.3M | ||
| Q3 25 | $11.1M | $48.6M | ||
| Q2 25 | — | $31.2M | ||
| Q1 25 | — | $48.9M | ||
| Q4 24 | — | $52.9M | ||
| Q3 24 | — | $76.3M | ||
| Q2 24 | — | $63.5M | ||
| Q1 24 | — | $82.3M |
| Q4 25 | — | $59.0M | ||
| Q3 25 | $198.3M | $26.5M | ||
| Q2 25 | — | $32.8M | ||
| Q1 25 | — | $33.8M | ||
| Q4 24 | — | $46.1M | ||
| Q3 24 | — | $65.5M | ||
| Q2 24 | — | $80.5M | ||
| Q1 24 | — | $96.2M |
| Q4 25 | — | $68.9M | ||
| Q3 25 | $212.0M | $54.2M | ||
| Q2 25 | — | $62.1M | ||
| Q1 25 | — | $77.7M | ||
| Q4 24 | — | $110.5M | ||
| Q3 24 | — | $135.2M | ||
| Q2 24 | — | $149.9M | ||
| Q1 24 | — | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.2M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.4M | ||
| Q3 25 | $1.2M | $17.4M | ||
| Q2 25 | — | $-17.7M | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $-23.4M | ||
| Q3 24 | — | $12.8M | ||
| Q2 24 | — | $-18.7M | ||
| Q1 24 | — | $5.9M |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
